Lappalainen J, Hietala J, Syvälahti E
Department of Pharmacology, University of Turku, Finland.
Psychopharmacology (Berl). 1989;98(4):472-5. doi: 10.1007/BF00441944.
The development of tolerance to the cataleptic effect of the selective D-1 antagonist SCH 23390 (0.5 mg/kg/day SC or 0.1 mg/kg/day SC) and haloperidol (1 mg/kg/day SC) during repeated administration was investigated. Catalepsy in rats was measured using the horizontal bar method. SCH 23390 induced a dose-related cataleptic effect of short duration, whereas the cataleptic effect of haloperidol appeared more slowly and lasted longer. Marked tolerance to the cataleptic effect of haloperidol developed already 6 days from the beginning of the treatment. The cataleptic effect of the higher dose regimen of SCH 23390 was also significantly reduced after 6 days' treatment. However, unlike haloperidol, this subacute tolerance was gradually reversed and was no longer significant after 12 and 18 days. The cataleptic response to the lower dose of SCH 23390 (0.1 mg/kg/day) was not significantly altered during the treatment and no initial catalepsy tolerance was observed with this dose regimen. These results suggest that different mechanisms are involved in the expression of cataleptic behaviour during chronic treatment with SCH 23390 and classical antipsychotics, such as haloperidol.
研究了重复给药期间对选择性D-1拮抗剂SCH 23390(0.5毫克/千克/天皮下注射或0.1毫克/千克/天皮下注射)和氟哌啶醇(1毫克/千克/天皮下注射)僵住效应的耐受性发展情况。使用水平杆法测量大鼠的僵住症。SCH 23390诱导出持续时间短的剂量相关僵住效应,而氟哌啶醇的僵住效应出现得更慢且持续时间更长。从治疗开始6天起就已对氟哌啶醇的僵住效应产生明显耐受性。6天治疗后,SCH 23390较高剂量方案的僵住效应也显著降低。然而,与氟哌啶醇不同,这种亚急性耐受性逐渐逆转,在12天和18天后不再显著。治疗期间对较低剂量SCH 23390(0.1毫克/千克/天)的僵住反应无明显改变,且该剂量方案未观察到初始僵住耐受性。这些结果表明,在使用SCH 23390和经典抗精神病药物(如氟哌啶醇)进行慢性治疗期间,僵住行为的表达涉及不同机制。